Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXTRIPHYLLINE PEDIATRIC vs AEROLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Xanthine derivative that inhibits phosphodiesterase, increasing cyclic AMP levels; antagonizes adenosine receptors, leading to bronchodilation, central nervous system stimulation, and positive inotropic effects.
Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
Symptomatic relief and prevention of bronchial asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
FDA-approved: Treatment of asthma and chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, bradycardia in preterm infants
200 mg orally every 6-8 hours; extended-release: 400-600 mg orally every 12 hours.
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
Neonates: 24-36 hours; Infants 1-6 months: 14-29 hours; Children 6-12 months: 9-18 hours; Children 1-9 years: 3-6 hours; Adults: 7-12 hours. Half-life prolonged in hepatic impairment, CHF, and COPD.
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Hepatic via CYP1A2, CYP2E1, and CYP3A4; major metabolite is 1-methyl-3-propylxanthine; exhibits non-linear kinetics at high doses.
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by xanthine oxidase and N-acetyltransferase. Metabolites excreted renally.
Renal (70-80% as unchanged drug, 10-15% as metabolites); biliary/fecal (<10%)
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
55-65% (primarily albumin).
65% bound to albumin
0.4-0.6 L/kg (increased in premature neonates and hepatic disease).
2.5 L/kg (extensive tissue distribution, suggests high lung penetration)
Oral immediate-release: 90-100%; Sustained-release: 80-95% (relative to immediate-release).
Oral: 40% (first-pass metabolism); Inhaled: 20% (lung deposition)
No specific guidelines; consider dose reduction in severe renal impairment (GFR <30 m L/min) to avoid accumulation.
No dose adjustment required for renal impairment. Drug is primarily hepatically metabolized and renally excreted as inactive metabolites; however, significant accumulation is not expected in renal dysfunction.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: reduce dose by 75% or avoid use.
Child-Pugh Class A: No dose adjustment. Class B: Reduce dose to 50% of normal, monitor for adverse effects. Class C: Use with caution; reduce dose to 25-50% and monitor closely. Specific data for AEROLATE limited; adjust based on clinical response and tolerance.
1-9 years: 4 mg/kg/dose orally every 6 hours; 9-16 years: 3 mg/kg/dose orally every 6 hours; adjust based on serum theophylline levels (target 5-15 mcg/m L).
Children 4-11 years: 1-2 inhalations (90 mcg each) twice daily; maximum 2 inhalations twice daily. Children 12 years and older: Same as adult dosing. Administer via inhaler with spacer for optimal delivery. Weight-based dosing not typically used; fixed doses per age group.
Start at 200 mg orally every 12 hours (extended-release) and titrate slowly; monitor serum theophylline levels closely due to reduced clearance.
No specific dose adjustment required. Use lowest effective dose due to potential for increased systemic exposure from reduced clearance and higher risk of adverse effects (e.g., osteoporosis, hyperglycemia). Monitor for cardiac effects and adrenal suppression.
No FDA boxed warning.
No FDA black box warning.
Risk of toxicity (seizures, cardiac arrhythmias) at serum levels >20 mcg/m L,Reduce dose in hepatic impairment, heart failure, and with drugs that inhibit metabolism (e.g., cimetidine, ciprofloxacin),Monitor serum theophylline concentrations
Monitor serum theophylline levels due to narrow therapeutic index (10-20 mcg/m L).,Risk of toxicity at high levels: seizures, arrhythmias, death.,Use with caution in patients with hepatic impairment, heart failure, fever, or elderly.,Cigarette smoking and certain drugs (e.g., rifampin, phenytoin) induce metabolism; others (e.g., cimetidine, macrolides) inhibit metabolism.
Hypersensitivity to oxitriphylline or any xanthine,Active peptic ulcer disease,Seizure disorder (unless adequately controlled)
Hypersensitivity to theophylline or any component.,Active peptic ulcer disease.,Uncontrolled seizure disorders.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate). High-fat meals may delay absorption; consistency in timing relative to meals is recommended. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance, reducing efficacy.
Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may potentiate CNS stimulation and toxicity. Food does not significantly affect absorption, but high-fat meals may delay absorption. Consistent dietary habits are recommended.
Oxtriphylline, a theophylline derivative, is classified as pregnancy category C. First trimester: Limited data, no known major malformations in humans; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: No specific risks, but maternal respiratory depression and fetal tachycardia may occur with high doses. Perinatal: Apnea, irritability, and jitteriness reported in neonates due to transplacental passage.
AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theophylline crosses the placenta and can cause fetal tachycardia, jitteriness, and irritability; apneic episodes and respiratory failure reported in neonates exposed near term. Risk of preterm labor and low birth weight associated with maternal asthma exacerbation.
Theophylline (active metabolite) is excreted into breast milk; M/P ratio approximately 0.6-0.8. Peak milk concentration occurs 2-3 hours after dose. Recommendations: Caution in preterm infants due to immature clearance; observe for irritability, insomnia, or feeding intolerance. Avoid if maternal dose exceeds moderate levels.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Peak milk levels occur 1-2 hours after maternal dosing. Estimated infant dose is about 1-10% of maternal weight-adjusted dose. Caution: irritability and jitteriness reported in breastfed infants. Avoid breastfeeding if maternal serum theophylline levels exceed 20 mcg/m L.
Pregnancy may reduce clearance and increase half-life of theophylline; volume of distribution increases slightly. Consider 20-30% dose reduction and monitor levels to avoid toxicity (target trough 8-12 mcg/m L). Third trimester: Dose may need further adjustment; postpartum levels may decrease (clearance returns to prepregnancy levels).
Pregnancy may increase theophylline clearance (especially in second and third trimesters) due to increased renal perfusion and hepatic metabolism. Dose adjustments often required to maintain therapeutic levels. Initiate at standard dose and titrate based on serum levels and clinical response. Postpartum clearance decreases rapidly; doses should be reduced to pre-pregnancy levels within 2-4 weeks after delivery.
Oxtriphylline is the choline salt of theophylline, providing 64% anhydrous theophylline by weight. Monitor serum theophylline levels, maintaining therapeutic range 5-15 mcg/m L. Avoid in patients with active peptic ulcer disease or seizure disorders unless on anticonvulsants. Taper dose to avoid rebound bronchospasm. Use with caution in hepatic impairment, COPD, and elderly, as clearance is reduced.
AEROLATE (theophylline) has a narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders unless essential. Caution with hepatic impairment, heart failure, and in elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides, and CYP1A2 inhibitors increase levels; smoking and rifampin decrease levels.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid taking with large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects like nausea, jitteriness, and insomnia.,Report symptoms of toxicity: persistent nausea, vomiting, severe headache, rapid or irregular heartbeat, or seizures.,Do not change brands or formulations without consulting your healthcare provider.,Inform all healthcare providers that you are taking this medication.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without informing your doctor, as smoking affects the drug's metabolism.,Keep a list of all medications you take, including over-the-counter drugs and herbal supplements.
"Oxtriphylline, a xanthine derivative, is a prodrug of theophylline and is primarily metabolized by hepatic cytochrome P450 enzymes, notably CYP1A2 and CYP3A4. Nevirapine, a non-nucleoside reverse transcriptase inhibitor, induces CYP3A4 and other metabolic enzymes, potentially increasing the clearance of oxtriphylline's active metabolite theophylline. This reduction in theophylline exposure may decrease its bronchodilator efficacy, leading to worsening of respiratory symptoms in patients with asthma or COPD."
"Oxtriphylline, a xanthine bronchodilator, is metabolized primarily by CYP1A2 and CYP3A4. Azithromycin, a macrolide antibiotic, can inhibit CYP3A4, leading to decreased clearance of oxtriphylline and increased plasma concentrations. This may result in dose-related toxicity, including nausea, vomiting, tachycardia, and seizures."
"Oxtriphylline, a xanthine derivative used as a bronchodilator, may inhibit the metabolism of abiraterone, a CYP3A4 substrate, leading to increased serum concentrations of abiraterone. This elevation can potentiate the risk of abiraterone-related adverse effects such as hepatotoxicity, hypertension, hypokalemia, and fluid retention. Additionally, Oxtriphylline's own clearance may be affected, increasing the likelihood of xanthine toxicity manifesting as nausea, vomiting, or cardiac arrhythmias."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXTRIPHYLLINE PEDIATRIC vs AEROLATE, answered by our medical review team.
OXTRIPHYLLINE PEDIATRIC is a Bronchodilator that works by Xanthine derivative that inhibits phosphodiesterase, increasing cyclic AMP levels; antagonizes adenosine receptors, leading to bronchodilation, central nervous system stimulation, and positive inotropic effects.. AEROLATE is a Bronchodilator that works by Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXTRIPHYLLINE PEDIATRIC and AEROLATE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXTRIPHYLLINE PEDIATRIC is: 200 mg orally every 6-8 hours; extended-release: 400-600 mg orally every 12 hours.. The standard adult dose of AEROLATE is: For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXTRIPHYLLINE PEDIATRIC and AEROLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXTRIPHYLLINE PEDIATRIC is classified as Category C. Oxtriphylline, a theophylline derivative, is classified as pregnancy category C. First trimester: Limited data, no known major malformations in humans; animal studies show no terat. AEROLATE is classified as Category C. AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.